Data / Drug companies / Hikma Pharmaceuticals USA Inc.
Hikma Pharmaceuticals USA Inc.: 165 products in the FDA NDC directory, labeler code 0641
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Hikma Pharmaceuticals USA Inc. (labeler code 0641) lists 165 products in the FDA National Drug Code Directory, covering 47 finished drugs by generic name. By type: 165 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 28, 2026.
The request: Watch Hikma Pharmaceuticals USA Inc. (FDA labeler code 0641): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0641
- Products in commercial distribution
- 165
- Packages
- 178
- Finished drugs by generic name
- 47
- Prescription products
- 165
- Over the counter products
- 0
- Controlled substance products
- Schedule II 28, Schedule IV 32
- Flagged as original packager
- 144 of 144 products that carry the flag
- Started marketing in the last 12 months
- 4
- Earliest marketing start
- June 16, 1959
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 120 | 72.7% |
| New drug applications (NDA) | 42 | 25.5% |
| Other unapproved drugs | 3 | 1.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 165 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 143 | 86.7% |
| Injection, solution | 15 | 9.1% |
| Injection, powder, for solution | 3 | 1.8% |
| Injection, emulsion | 3 | 1.8% |
| Injectable, liposomal | 1 | 0.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sugammadex | 0641-6270 | Injection | Generic drugs (ANDA) | July 28, 2026 |
| Diazepam | 0641-6283 | Injection, solution | Generic drugs (ANDA) | July 8, 2026 |
| Atropine Sulfate | 0641-6275 | Injection | Generic drugs (ANDA) | November 7, 2025 |
| Atropine Sulfate | 0641-6274 | Injection | Generic drugs (ANDA) | November 7, 2025 |
| Fentanyl Citrate | 0641-6290 | Injection | New drug applications (NDA) | August 29, 2025 |
| Fentanyl Citrate | 0641-6289 | Injection | New drug applications (NDA) | August 29, 2025 |
| Glycopyrrolate | 0641-6213 | Injection | New drug applications (NDA) | August 28, 2025 |
| Glycopyrrolate | 0641-6212 | Injection | New drug applications (NDA) | August 28, 2025 |
| Naloxone Hydrochloride | 0641-6193 | Injection | Generic drugs (ANDA) | July 25, 2025 |
| Methadone Hydrochloride | 0641-6266 | Injection | Generic drugs (ANDA) | June 12, 2025 |
| Hydromorphone Hydrochloride | 0641-6254 | Injection, solution | New drug applications (NDA) | May 13, 2025 |
| Morphine Sulfate | 0641-6192 | Injection | Generic drugs (ANDA) | April 18, 2025 |
| Morphine Sulfate | 0641-6191 | Injection | Generic drugs (ANDA) | April 18, 2025 |
| Ephedrine Sulfate | 0641-6236 | Injection | Generic drugs (ANDA) | December 20, 2024 |
| Sodium Acetate | 0641-6263 | Injection | Generic drugs (ANDA) | May 20, 2024 |
| Sodium Acetate | 0641-6262 | Injection | Generic drugs (ANDA) | May 20, 2024 |
| Sodium Acetate | 0641-6261 | Injection | Generic drugs (ANDA) | May 20, 2024 |
| Hydromorphone Hydrochloride | 0641-6259 | Injection | Generic drugs (ANDA) | April 26, 2024 |
| Hydromorphone Hydrochloride | 0641-6206 | Injection | Generic drugs (ANDA) | April 26, 2024 |
| Hydromorphone Hydrochloride | 0641-6170 | Injection | Generic drugs (ANDA) | April 26, 2024 |
| Hydromorphone Hydrochloride | 0641-6169 | Injection | Generic drugs (ANDA) | April 26, 2024 |
| Midazolam | 0641-6220 | Injection | Generic drugs (ANDA) | March 29, 2024 |
| Midazolam | 0641-6219 | Injection | Generic drugs (ANDA) | March 29, 2024 |
| Midazolam | 0641-6218 | Injection | Generic drugs (ANDA) | March 29, 2024 |
| Caffeine Citrate | 0641-6267 | Injection | New drug applications (NDA) | January 11, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.